|
|

Title: Extended release acetaminophen particles
United States Patent: 6,126,967
Inventors: Clemente; Emmett (Manchester, MA); Anaebonam;
Aloysius O. (Burlington, MA); Mendes; Robert W. (Dedham, MA); Fawzy; Abdel
A. (Dracut, MA); Morrel; Eric M. (Medfield, MA)
Assignee: Ascent Pediatrics (Wilmington, MA)
Appl. No.: 146248
Filed: September 3, 1998
Abstract
An extended release acetaminophen composition comprises a plurality of
discrete particles containing acetaminophen which, when contained within a
gelatin capsule and assayed in a USP Apparatus I rotating basket at 50 rpm
in 900 mL of phosphate buffer at pH 5.8 and 37oC., exhibits
about 40 percent to about 53 percent acetaminophen dissolution at one-half
hour, about 50 percent to about 68 percent dissolution at 45 minutes,
about 57 percent to about 77 percent acetaminophen dissolution at one
hour, and about 82 percent to about 92 percent acetaminophen dissolution
at two hours. After six hours, the contemplated extended release
acetaminophen composition exhibits substantially complete dissolution. A
process for treating a human patient with the extended release
acetaminophen composition is also disclosed.
SUMMARY OF THE INVENTION
The present invention contemplates an extended release
composition of acetaminophen in the form of generally spherical particles.
The particles can be packaged in a gelatin capsule or a blister, and the
contents administered in the gelatin capsule to adults that can swallow
such capsules or the contents of the capsule or blister can be emptied
therefrom and dispersed in an edible medium such as applesauce that can be
swallowed by patients such as children that cannot swallow or have
difficulty swallowing tablets, caplets or capsules.
The extended release acetaminophen composition comprises a plurality of
discrete particles containing acetaminophen which, when contained within a
gelatin capsule and assayed in a USP Apparatus I rotating basket at 50 rpm
in 900 milliliters (mL) of phosphate buffer at pH 5.8 and 37oC.
exhibits about 40 percent to about 53 percent acetaminophen released at
one-half hour, about 50 percent to about 68 percent released at 45
minutes, about 57 percent to about 77 percent acetaminophen released at
one hour, and about 82 percent to about 92 percent acetaminophen released
at two hours. After six hours, the contemplated extended release
acetaminophen exhibits substantially complete release.
Even though there appears to be overlap of the dissolution values at
various times and subsequent, adjacent times, it is to be understood that
a dissolution value within a stated range of values at a particular time
increases from that dissolution value at a later time. As a consequence,
even though the upper limit for a previously recited time frame can
overlap with a lower limit from a subsequent time frame, an individual
sample exhibits greater dissolution values until substantially complete
dissolution is achieved.
Advantageously, a contemplated extended release acetaminophen composition
provides an extended or sustained release profile in a particle-or prill-
containing gelatin capsule or blister. A contemplated composition can thus
be dispersed or sprinkled on, for example, food such as applesauce, so
that it can be administered to a patient that, otherwise has difficulty
taking, or could not take a "solid" tablet or caplet. Thus, the
present extended release composition now provides long term analgesic
administration for patients who otherwise could not obtain such relief.
It is to be understood that reference herein to gelatin capsule, capsule
or blister is made only for the purpose of describing or providing various
alternate packaging or "containing" vehicles for the composition
of the present invention, and is not intended to limit the scope of the
present invention. All such packaging or "containing" vehicles
are thus within the scope of the present invention.
One exemplary composition comprises particles containing acetaminophen
coated on sugar/starch seeds. All of these particles are free of a wicking
agent and an erosion promoter as required and utilized in U.S. Pat. No.
4,820,522. The particles are present as a blend of both an immediate
release and a controlled release form.
Preferably, the controlled release particles comprise a sugar/starch seed
particle coated with a plurality of layers of acetaminophen and magnesium
stearate that are bound with povidone. Most preferably, the
acetaminophen-containing layers are coated with a plurality of layers of a
mixture of povidone and magnesium stearate. In a contemplated composition,
the weight ratio of acetaminophen to magnesium stearate in the controlled
release particles is about 5:1 to about 10:1, and acetaminophen comprises
about 70 to about 80 weight percent of the controlled release particles.
In a preferred composition, the immediate release particles also comprise
sugar/starch seed particles, which seeds are coated with a plurality of
layers of a mixture of acetaminophen, starch and cross-linked
carboxymethyl cellulose bound with povidone. A preferred cross-linked
carboxymethyl cellulose is croscarmellose NF. In a preferred composition,
the immediate release particles contain acetaminophen, starch and
cross-linked carboxymethyl cellulose in a weight ratio of about
13-16:1:1.5-2, respectively, and acetaminophen constitutes about 60-70
weight percent of the particles.
A preferred blend of the composition includes immediate release particles
and controlled release particles in a weight ratio of about 1:1 to about
1:1.5, respectively.
The blend can also contain coated sugar/starch seeds that are free of
acetaminophen. In one such blend, the immediate release particles, the
controlled release particles and the coated sugar/starch seeds are present
in a weight ratio of about 1:1-1.5:0.1-0.25.
Another exemplary composition comprises acetaminophen particles coated
with each of a first, second and third layer, the first and third layers
being hydroxypropyl cellulose and the second layer being ethylcellulose.
Preferably, the weight ratio of each the first, second and third layers on
a bead is about 1:4-6:1, respectively, and the acetaminophen constitutes
about 92 to about 94 weight percent of each bead.
Most preferably, the beads are sized so that about 90 percent by weight
pass through a 20 mesh sieve screen and about 90 percent by weight are
retained on an 80 mesh sieve screen.
A process for treating a human patient that has difficulty swallowing
acetaminophen in tablet, caplet or capsule form includes the steps of
distributing an effective amount of the particles in a pharmaceutically
acceptable palatable medium to form an acetaminophen particle-containing
medium and administering the acetaminophen particle-containing medium to
the human patient.
The present process is particularly contemplated for administering the
composition to human patients that are about three months to about 14
years old, and particularly to children 2 to about 11 years old, including
children that are febrile. However, the composition can be used by others
that may have difficulty swallowing a tablet, caplet or capsule, or it can
be used by those that do not have difficulty taking such "solid"
non-dispersible medication forms.
Claim 1 of 18 Claims
What is claimed is:
1. An extended release acetaminophen composition comprising a plurality of
discrete particles containing acetaminophen which, when contained within a
gelatin capsule and assayed in a USP 23/NF 18 Apparatus I rotating basket
at 50 rpm in 900 mL of phosphate buffer at pH 5.8 and 37oC.
exhibits about 40 percent to about 53 percent acetaminophen dissolution at
one-half hour, about 50 percent to about 68 percent dissolution at 45
minutes, about 57 percent to about 77 percent acetaminophen dissolution at
one hour, about 82 percent to about 92 percent acetaminophen dissolution
at two hours and about 100 percent dissolution at six hours.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|